作为新兴肺纤维化治疗药物的化物:分类,机制和转化潜力
Yafang Wang1, Chunlei Hua2, Henghui Zhang3
1Department of Rheumatology and Immunology, Inner Mongolia Autonomous Region People's Hospital, Hohhot, China.
Chemistry & biodiversity
|August 20, 2025
概括
通过向多种途径,天然类药物在治疗肺纤维化 (PF) 中具有前景. 本综述综合了关于其抗炎,抗氧化和抗瘤作用的研究,以预防和治疗PF.
科学领域:
- 药理学
- 肺病学
- 自然产品化学
背景情况:
- 肺纤维化是一种渐进的肺病,治疗选择有限.
- 自然产品,特别是类,正在成为潜在的治疗药物.
- 类药物提供了一种多重目标的方法来对抗PF病理.
研究的目的:
- 系统地审查化物在预防和治疗肺纤维化的作用机制.
- 综合目前基于类药物的实验和临床研究结果.
- 确定新的PF治疗开发的挑战和未来的研究方向.
主要方法:
- 对化物和肺纤维化的实验和临床研究进行全面的文献搜索.
- 在PF模型中分析化物向的信号通路.
- 对PF相关的类化合物的抗炎,抗氧化和抗质作用的评估.
主要成果:
- 类药物在抑制细胞外基质沉积方面表现出有效性.
- 它们保护膜上皮细胞,抑制肺纤维细胞的激活和增殖.
- 多种信号通路由化物调节以产生抗PF效应.
结论:
- 类是肺纤维化治疗的有前途的天然化合物.
- 它们的多目标机制比传统疗法具有优势.
- 需要进一步的研究来将这些发现转化为PF的临床应用.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
285
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
285
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
256
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
256
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
Drugs Used in Lower Respiratory Disorders: Overview
578
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
578


